Rational Drug Design is a process of developing and discovering new drugs by studying the target of the drug. The intended target of a drug is usually a protein or receptor which can be activated or blocked when targeted by a drug. In order for rational drug design to be effective, the investigators must first obtain significant knowledge of the target including its structure, function, and mechanisms in which it participates.
Ever wonder what you’re missing in your data? The sheer complexity of today’s flow and mass cytometry datasets demands automated solutions. Machine learning plugins only provide...
In the last 5 years, the US Food and Drug Administration has approved 4 anti-CD19 chimeric antigen receptor T cell (CART19) products for relapsed/refractory B cell lymphomas and leukemia. Ho...
My laboratory uses tools from pharmacology, genomics, and cell signaling to study two key aspects of cancer biology. First, we seek to understand how oncogenic signals, altered metabolic sta...
Date: November 16, 2021 Time: 9:00am (PDT), 12:00pm (EDT) Discovery in biological research was historically driven by empirical methods. The advent of biological engineering, propelled by te...
Date: July 27, 2021 Time: 9:00am PDT Dr. Yuri Iozzo presents "An integrated structural biology platform specialized for sub-100 kDa protein complexes to support biologics discovery and...
Date: June 24, 2021 Time: 9:00am PDT Currently, there are insufficient therapies to fully eradicate human cancer or predict who it will strike. Rational-drug design based on structural insi...
G protein-coupled receptors (GPCRs) are among the most intensively studied drug targets, and account for about ~34% of all drugs approved by the FDA. Examples of drugs targeting GPCRs includ...
This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
DATE: November 19, 2020 TIME: 9:00am PT, 12am ET Knowledge of the three-dimensional structure of therapeutically relevant targets has become an essential step in the pipeline of drug discove...
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
CRISPR-based genome editing has accelerated biological research and holds great potential for studying and treating human diseases. The CRISPR-Cas9 system requires a Cas9 nuclease and a guid...
Combinatorial inhibition of effector and feedback pathways is a promising treatment strategy for KRAS mutant cancers. However, the particular pathways that should be targeted to optimize the...
A key step in the clinical production of CAR T cells is the expansion of engineered T cells. To generate enough cells for viable adoptive cell therapy, cells must be robustly stimulated, whi...
Our laboratory uses tools from pharmacology, genomics, and cell signaling to identify new precision anticancer therapeutic strategies. Under this broad heading, our work involves three key a...
Recent advances in DNA sequencing and omics-based capabilities are revealing incredible therapeutic opportunities and quickly transforming drug discovery. Molecularly targeted drugs aim to e...
The efficacy of current influenza antiviral drugs is compromised by emerging drug resistance. To address this unmet medical need, we have made progress in developing novel influenza antiviral...
Recent advances in genomic technologies have revealed enormous complexities and uniqueness of human physiology. Although enormous efforts are being made to apply this knowledge to enhance the...
Recent clinical successes in cancer genome-inspired personalized medicine have been a major breakthrough in drug discovery. However, 98% of the patients have an incomplete therapeutic respons...
Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired resistance. How tumors transition between...
Advances in genomic research have led to identification of the majority of the drivers of tumor progression. However, our understanding of the molecular mechanisms propelling tumor growth is...
Cancer and diabetes are complex diseases that have proven difficult to treat in the clinics. Until recently, most efforts have focused on hitting individual therapeutic targets cleanly. Unfor...
Ever wonder what you’re missing in your data? The sheer complexity of today’s flow and mass cytometry datasets demands automated solutions. Machine learning plugins only provide...
In the last 5 years, the US Food and Drug Administration has approved 4 anti-CD19 chimeric antigen receptor T cell (CART19) products for relapsed/refractory B cell lymphomas and leukemia. Ho...
My laboratory uses tools from pharmacology, genomics, and cell signaling to study two key aspects of cancer biology. First, we seek to understand how oncogenic signals, altered metabolic sta...
Date: November 16, 2021 Time: 9:00am (PDT), 12:00pm (EDT) Discovery in biological research was historically driven by empirical methods. The advent of biological engineering, propelled by te...
Date: July 27, 2021 Time: 9:00am PDT Dr. Yuri Iozzo presents "An integrated structural biology platform specialized for sub-100 kDa protein complexes to support biologics discovery and...
Date: June 24, 2021 Time: 9:00am PDT Currently, there are insufficient therapies to fully eradicate human cancer or predict who it will strike. Rational-drug design based on structural insi...
G protein-coupled receptors (GPCRs) are among the most intensively studied drug targets, and account for about ~34% of all drugs approved by the FDA. Examples of drugs targeting GPCRs includ...
This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
DATE: November 19, 2020 TIME: 9:00am PT, 12am ET Knowledge of the three-dimensional structure of therapeutically relevant targets has become an essential step in the pipeline of drug discove...
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
CRISPR-based genome editing has accelerated biological research and holds great potential for studying and treating human diseases. The CRISPR-Cas9 system requires a Cas9 nuclease and a guid...
Combinatorial inhibition of effector and feedback pathways is a promising treatment strategy for KRAS mutant cancers. However, the particular pathways that should be targeted to optimize the...
A key step in the clinical production of CAR T cells is the expansion of engineered T cells. To generate enough cells for viable adoptive cell therapy, cells must be robustly stimulated, whi...
Our laboratory uses tools from pharmacology, genomics, and cell signaling to identify new precision anticancer therapeutic strategies. Under this broad heading, our work involves three key a...
Recent advances in DNA sequencing and omics-based capabilities are revealing incredible therapeutic opportunities and quickly transforming drug discovery. Molecularly targeted drugs aim to e...
The efficacy of current influenza antiviral drugs is compromised by emerging drug resistance. To address this unmet medical need, we have made progress in developing novel influenza antiviral...
Recent advances in genomic technologies have revealed enormous complexities and uniqueness of human physiology. Although enormous efforts are being made to apply this knowledge to enhance the...
Recent clinical successes in cancer genome-inspired personalized medicine have been a major breakthrough in drug discovery. However, 98% of the patients have an incomplete therapeutic respons...
Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired resistance. How tumors transition between...
Advances in genomic research have led to identification of the majority of the drivers of tumor progression. However, our understanding of the molecular mechanisms propelling tumor growth is...
Cancer and diabetes are complex diseases that have proven difficult to treat in the clinics. Until recently, most efforts have focused on hitting individual therapeutic targets cleanly. Unfor...
Opens in a new windowOpens an external siteOpens an external site in a new window